NCT02143804 2026-04-02
exBOND
CG Oncology, Inc.
Phase 2 Withdrawn
Clinical Trials
10 trialsNCT05564416 2025-10-21
Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT06424717 2024-09-27
Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has Progressed on Prior Anti-PD-(L)1 Therapy (JAVELIN DDRiver Bladder)
EMD Serono
Phase 2 Withdrawn
NCT03517995 2020-05-28
Randomized, Phase II Clinical Trial of Sulforaphane in Bladder Cancer Chemoprevention
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Withdrawn
NCT04040725 2019-12-17
Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 Overexpression
Dana-Farber Cancer Institute
Phase 2 Withdrawn
NCT03150836 2017-10-19
Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer
University of California, San Francisco
Phase 2 Withdrawn
NCT01907308 2014-04-29
Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial Carcinoma
University of Colorado, Denver
Phase 2 Withdrawn
NCT01639521 2014-01-29
Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer
University of Southern California
Phase 2 Withdrawn
NCT01700010 2013-01-17
Trial of Lapatinib and Weekly Paclitaxel for Advanced Urothelial Cancer
University of Michigan Rogel Cancer Center
Phase 2 Withdrawn
NCT00824811 2012-08-02
Topical Cyclosporine vs. Placebo for Epiphora Associated With Docetaxel
M.D. Anderson Cancer Center
Phase 2 Withdrawn